Onkologie. 2014:8(2):86-91

Modern trends in the treatment of advanced malignant melanoma

Radek Lakomý1, Alexandr Poprach1, Renata Koukalová2, Jiří Šána3
1 Lékařská fakulta, Masarykova univerzita, Brno a Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
2 Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno
3 CEITEC &ndash, Středoevropský technologický institut, Masarykova univerzita, Brno a Klinika komplexní

The standard treatment of advanced malignant melanoma was radically changed. The available chemotherapy and immunotherapy have

not been able to significantly prolong survival of our patients before 2011. The progress has been made with targeted therapy (BRAF and

MEK inhibitors) and modern immunotherapy (antibody against CTLA-4 and potentially PD-1/PD-L1). Combinations of targeted drugs are

being intensively studied to delay or prevent of resistance and tumor progression. New molecular targets are needed, particularly for

patients without BRAF mutations. The evolving knowledge of optimal combinations and sequence of therapeutic agents is important to

overcome limitations of current treatment.

Keywords: melanoma, immunotherapy, targeted therapy

Published: May 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lakomý R, Poprach A, Koukalová R, Šána J. Modern trends in the treatment of advanced malignant melanoma. Onkologie. 2014;8(2):86-91.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dusek L, Muzik J, Kubasek M, et al. Epidemiology of malignant tumours in the Czech Republic [online], [cit. 2014-1-28]. Masaryk University, 2005. Available from: http://www.svod.cz.
    2. Serrone L, Zeuli M, Sega FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
    3. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have learned in 30 years? Eur J Cancer 2004; 40: 1825-36. Go to original source... Go to PubMed...
    4. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26: 3445-3455. Go to original source... Go to PubMed...
    5. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558;ONO-4538). J Clin Oncol 2013; 31: 549 (suppl; abstr CRA9006). Go to original source...
    6. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144. Go to original source... Go to PubMed...
    7. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133. Go to original source... Go to PubMed...
    8. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013; 31: 550s (suppl; abstr 9010). Go to original source...
    9. Hodi FS, O´Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723. Go to original source... Go to PubMed...
    10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526. Go to original source... Go to PubMed...
    11. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Presented at: European Cancer Congress 2013 (ECCO-ESMO-ESTRO); September 27-October 1, 2013; [cit. 2014-1-28]. Amsterdam, The Netherlands. Abstract 24. Avaible from: http://www.onclive.com/conference-coverage/ecco-esmo-2013/Pooled-Analysis-Reinforces-Long-Term-Survival-Benefit-With-Ipilimumab#sthash.ywMNHpeA.dpuf.
    12. Ribas A, Kim KB, Schuchter LM, et al., BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29(Suppl 15): Abstract 8509. Go to original source...
    13. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-16. Go to original source... Go to PubMed...
    14. Larkin JMG, Del Vecchio M, Ascierto PA, et al. Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma. J Clin Oncol 2013: 31(suppl; abstr 9046). Go to original source... Go to PubMed...
    15. Harding JJ, Catalanotti F, Yaqubie A, et al. Vemurafenib in patients with BRAF-mutant melanoma and brain metastases. J Clin Oncol 2013; 31(suppl; abstr 9060). Go to original source... Go to PubMed...
    16. Heneberg P. Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition. Klin Onkol 2011; 24(4): 256-264. Go to PubMed...
    17. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380(9839): 358-365. Go to original source... Go to PubMed...
    18. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 study. Lancet Oncol 2012; 13(11): 1087-1095. Go to original source... Go to PubMed...
    19. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367(2): 107-114. Go to original source... Go to PubMed...
    20. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367(18): 1694-1703. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.